Stockreport
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion [Yahoo! Finance]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Gilead Sciences (GILD) had its price target raised by Daiwa Securities Group Inc. from $129.00 to $161.00. They now have an "outperform" rating on the stock.[MarketBeat]
- CNBC Changemakers and Power Players Podcast: Gilead Sciences Chief Commercial & Corporate Affairs Officer and 2026 CNBC Changemaker Johanna Mercier on ending HIV epidemic, life hacks, and her leadership superpower [CNBC][CNBC]
- Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy [Yahoo! Finance][Yahoo! Finance]
- Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy[Business Wire]
- 2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 2/24/26 - Form 10-K
- 2/23/26 - Form 8-K
- 2/18/26 - Form 4
- GILD's page on the SEC website
- More